Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
P Ozieranski, L Martinon, PA Jachiet, S Mulinari - BMJ open, 2021 - bmjopen.bmj.com
Objectives To examine the accessibility and quality of drug company payment data in
Europe. Design Comparative policy review of payment data in countries with different …
Europe. Design Comparative policy review of payment data in countries with different …
Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform
Conflicts of interest (COIs) in healthcare are increasingly discussed in the literature, yet
these relationships continue to influence healthcare. Research has consistently shown that …
these relationships continue to influence healthcare. Research has consistently shown that …
[HTML][HTML] International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and …
Background Self-regulation of payment disclosure by pharmaceutical industry trade groups
is a major global approach to increasing transparency of financial relationships between …
is a major global approach to increasing transparency of financial relationships between …
Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019
A Murayama, M Hoshi, H Saito, S Kamamoto… - Respiration, 2022 - karger.com
Background: Financial relationships between healthcare professionals and pharmaceutical
companies have historically caused conflicts of interest and unduly influenced patient care …
companies have historically caused conflicts of interest and unduly influenced patient care …
Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019
A Murayama, S Kamamoto, M Kawashima, H Saito… - BMJ open, 2023 - bmjopen.bmj.com
Objectives Limited evidence is available regarding the financial relationships between
gastroenterologists and pharmaceutical companies in Japan. This study analysed the …
gastroenterologists and pharmaceutical companies in Japan. This study analysed the …
Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of …
Objective To provide an overview of non-research pharmaceutical payments to healthcare
organizations and professionals in Japan and evaluate data disclosure methods. Methods …
organizations and professionals in Japan and evaluate data disclosure methods. Methods …
[HTML][HTML] Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven …
S Mulinari, L Martinon, PA Jachiet, P Ozieranski - Health Policy, 2021 - Elsevier
The European pharmaceutical industry uses the alleged efficacy of self-regulation to
question the need for transparency laws similar to the US Physician Payment Sunshine Act …
question the need for transparency laws similar to the US Physician Payment Sunshine Act …
[HTML][HTML] Characteristics and distribution of scholarship donations from pharmaceutical companies to Japanese Healthcare institutions in 2017: A cross-sectional …
A Murayama, S Kamamoto, H Saito… - … Journal of Health …, 2023 - ncbi.nlm.nih.gov
Background: Financial relationships between healthcare institutions and pharmaceutical
companies can lead to conflicts of interest (COIs), potentially compromising patients' care. In …
companies can lead to conflicts of interest (COIs), potentially compromising patients' care. In …
[HTML][HTML] Assessment of financial relationships between otorhinolaryngologists and pharmaceutical companies in Japan between 2016 and 2019
S Kamamoto, A Ozaki, A Murayama - Cureus, 2023 - ncbi.nlm.nih.gov
Introduction: There are prevalent financial relationships between physicians and the
pharmaceutical industry in medical specialties, including otorhinolaryngology. Although …
pharmaceutical industry in medical specialties, including otorhinolaryngology. Although …
Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan
Abstract Introduction and hypothesis In Japan, the authors of urology clinical practice
guidelines (UCPG) used in patient-centered care are often targeted by pharmaceutical …
guidelines (UCPG) used in patient-centered care are often targeted by pharmaceutical …